⌘K
Loading ticker…
As of 2026-08-21, enGene Therapeutics Inc. Common Stock (ENGN) has a 3-month relative strength percentile of 53 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 35. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.6%, relative volume 0.36×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ENGN is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -0.6% / -69.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ENGN appears in 1 ETF as of Apr 2026: BBC at 0.64% weight, $237K notional.
Held by 1 ETFs · $237K across latest filings · largest weight 0.64% (BBC).
Top 1 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| BBC | 0.64% | $237K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ENGN Jan avg: -2.92% median: 0.75% win: 67% σ: 10.78% n: 3 2023-11-02 → 2026-07-31 | ENGN Feb avg: 27.98% median: 6.09% win: 67% σ: 52.74% n: 3 2023-11-02 → 2026-07-31 | ENGN Mar avg: -14.39% median: -25.46% win: 33% σ: 25.64% n: 3 2023-11-02 → 2026-07-31 | ENGN Apr avg: -2.34% median: -6.19% win: 33% σ: 7.91% n: 3 2023-11-02 → 2026-07-31 | ENGN May avg: -42.17% median: -44.72% win: 0% σ: 33.73% n: 3 2023-11-02 → 2026-07-31 | ENGN Jun avg: -1.47% median: -5.21% win: 33% σ: 7.61% n: 3 2023-11-02 → 2026-07-31 | ENGN Jul avg: 2.78% median: 3.47% win: 100% σ: 1.79% n: 3 2023-11-02 → 2026-07-31 | ENGN Aug avg: -2.31% median: -2.31% win: 50% σ: 34.24% n: 2 2023-11-02 → 2026-07-31 (current) | ENGN Sep avg: 21.20% median: 21.20% win: 50% σ: 37.67% n: 2 2023-11-02 → 2026-07-31 | ENGN Oct avg: 19.83% median: 19.83% win: 100% σ: 20.17% n: 2 2023-11-02 → 2026-07-31 | ENGN Nov avg: -17.34% median: -2.26% win: 33% σ: 39.06% n: 3 2023-11-02 → 2026-07-31 | ENGN Dec avg: 3.09% median: 11.90% win: 67% σ: 23.10% n: 3 2023-11-02 → 2026-07-31 |